The antidepressant and antiinflammatory effects of rolipram in the central nervous system

CNS Drug Reviews

Volumn 7, Issue 4, 2001, Pages 387-398

  Zhu, Jie ^a   Mix, Eilhard ^b   Winblad, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

cAMP; Central nervous system (CNS); Phosphodiesterases; Rolipram

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYPROHEPTADINE; CYTOKINE; NORADRENALIN; PHENOXYBENZAMINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PIZOTIFEN; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOXICITY; DRUG USE; HUMAN; INFLAMMATION; NEUROPHARMACOLOGY; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 0035727846     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00206.x     Document Type: Review

References (83)

1. Protective effect of rolipram in experimental autoimmune neuritis: Protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system
2. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: Relation to inflammatory cytokines and modulation by dexamethasone and rolipram
3. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication
4. 3H]rolipram binding in the rat brain
5. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site
6. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide
7. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach
8. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo
9. Therapeutic potential of phosphodiesterase-4 and-3 inhibitors in Th1-mediated autoimmune diseases
10. Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats
11. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives
12. High-affinity cAMP phosphodiesterase and adenosine localized in sensory organs
13. Lymphocyte suppression by rolipram with other immunosuppressive drugs
14. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline
15. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides
16. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition
17. Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells
18. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse
19. Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline
20. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease
21. Expression and regulation of human and rat phosphodiesterase type IV isogenes
22. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors
23. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells
24. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones
25. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors
26. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus
27. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor
28. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice
29. Anti-inflammatory and immunomodulatory potential of the novel PDE IV inhibitor roflumilast in vitro
30. Emetic, central nervous system, and pulmonary activities of rolipram in the dog
31. Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine
32. Neurotransmitters in anxiety
33. Inhibiting the inflammatory response in joint sepsis
34. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys
35. Regulation of human immunodeficiency virus type 1 replication in human T lymphocytes by nitric oxide
36. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats
37. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain
38. Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: Expression of both p55 and p75 subunits is affected
39. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences
40. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats
41. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells
42. Rapid regulation of a cyclic AMP-specific phosphodiesterase (PDE IV) by forskolin and isoproterenol in LRM55 astroglial cells
43. Tumor necrosis factor-alpha is chemokinetic for lymphokine-activated killer cells: Regulation by cyclic adenosine monophosphate
44. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human
45. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: Sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase
46. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice
47. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones] as PDE 4 inhibitors
48. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis
49. New pharmacological approaches to the management of depression: From theory to clinical practice
50. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells
51. Antidepressant effects of rolipram in a genetic animal model of depression: Cholinergic supersensitivity and weight gain
52. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry
53. Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis
54. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
55. The influence of rolipram on the central serotoninergic system
56. CGS 21680, dibutyryl cyclic AMP and rolipram attenuate the proinflammatory interactions of the Pseudomonas aeruginosa-derived pigment, 1-hydroxyphenazine, with human neutrophils
57. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis
58. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis
59. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
60. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
61. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID
62. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats
63. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes beta-adrenoceptor subsensitivity in rat cerebral cortex
64. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): A potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain
65. In-patient major depression: Is rolipram as effective as amitriptyline?
66. + T cell hyperactivation and HIV type 1 replication
67. cAMP-dependent protein kinase activity in major depression
68. Pruritus in HIV-1 disease: Therapy with drugs which may modulate the pattern of immune dysregulation
69. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
70. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease
71. The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality
72. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A (2A) receptor agonists
73. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function
74. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma
75. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis
76. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat
77. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors
78. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors
79. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility
80. Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices
81. Results of a phase II study of the antidepressant effect of rolipram
82. Pleiotropic effects of HIV-1 protein R (Vpr) on morphogenesis and cell survival in fission yeast and antagonism by pentoxifylline
83. Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats